Showing 5061-5070 of 8474 results for "".
- Lupus Foundation of America Awards Five Summer Fellowship Grantshttps://practicaldermatology.com/news/lupus-foundation-of-america-awards-five-summer-fellowship-grants/2461899/The Lupus Foundation of America announced five recipients of the
- Reinforcement Learning Model May Boost AI Skin Cancer Diagnosis Accuracyhttps://practicaldermatology.com/news/reinforcement-learning-model-may-boost-ai-skin-cancer-diagnosis-accuracy/2461897/Artificial intelligence (AI) is already being used to diagnose skin cancer, but so far, it can’t keep pace with the complex decision-making of doctors in practice. Now, an international research team is developing a learning method in which greater accuracy in AI results can be a
- Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Developmenthttps://practicaldermatology.com/news/sirnaomics-appoints-dr-francois-lebel-as-senior-vice-president-for-preclinical-and-clinical-development/2461896/Dr. Francois Lebel, M.D is the new Senior Vice President for preclinical and clinical development at Sirnaomics Ltd. "With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarkin
- Taylor Harris Named New CEO at Cuterahttps://practicaldermatology.com/news/taylor-harris-named-new-ceo-at-cutera/2461892/Taylor Harris has been appointed Chief Executive Officer for Cutera, Inc., effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as memb
- Hoth Therapeutics Receives Protocol Approval for HT-001https://practicaldermatology.com/news/hoth-therapeutics-receives-protocol-approval-for-ht-001/2461873/Hoth Therapeutics, Inc. received approval from the Food & Drug Administration (FDA) for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for six weeks, during which the effect on treating acneiform rash and other skin
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bim
- Acclaro Medical Rebrands UltraClear Cold Fiber Laserhttps://practicaldermatology.com/news/acclaro-medical-rebrands-ultraclear-cold-fiber-laser/2461866/Meet the newly re-branded UltraClear Cold Fiber Laser from Acclaro Medical. From a design perspective, rebranding encompasses an updated logo and color palette and aims to increase recognition of UltraClear's 3DIntelliPulse technology and its ability to provide optima
- People Who Use Skin-Lightening Products May Be in the Dark About Riskshttps://practicaldermatology.com/news/people-who-use-skin-lightening-products-may-be-in-the-dark-about-risks/2461862/Skin-lightening products can be dangerous, but users aren’t always aware of the risks, a new study finds. To conduct the study, researchers sent an anonymous 19-question survey to individuals with skin of color in the U.S. asking about their demographics, colorism attitudes, skin
- Soligenix, Inc.’s SGX302 (Synthetic Hypericin) Demonstrates “Clear Biological Signal” in Phase 2a PsO Studyhttps://practicaldermatology.com/news/sgx302-synthetic-hypericin-demonstrates-clear-biological-signal-in-phase-2a-pso-study/2461854/Soligenix, Inc.’s SGX302 (synthetic hypericin) showed a clear
- Study: Men With Skin of Color Are More Likely to Die From Melanomahttps://practicaldermatology.com/news/study-men-with-skin-of-color-are-more-likely-to-doe-from-melanoma/2461853/Men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma, a new study in the Journal of the American Academy of Dermatology shows. "We know that men may be less likely to seek medical care than w